Tricuspid regurgitation (TR) disease stage may influence survival outcomes following tricuspid transcatheter edge-to-edge repair (T-TEER), according to a new analysis of 1-year follow-up data that suggests individuals with intermediate TR may receive the most substantial treatment benefits.